# Indivior

> Indivior develops and sells prescription medicines for opioid use disorder, led by the monthly buprenorphine injection Sublocade and the buprenorphine-naloxone film Suboxone. Spun out of Reckitt in 2014, the Virginia-based company is refocusing on addiction treatment and has shareholder approval for a proposed merger with Supernus, expected to close November 2, 2026.

- **Founded:** 2014
- **Headquarters:** North Chesterfield, United States
- **Products:** Sublocade, Suboxone Film, Subutex, OPVEE, Perseris
- **Notable:** Sublocade received FDA approval in 2017., FDA approved a rapid-initiation protocol and additional Sublocade injection sites in February 2025., Sublocade generated $856 million in 2025 net revenue.

## Products & services

- **Sublocade** — Monthly extended-release buprenorphine injection for moderate to severe opioid use disorder; administered by healthcare professionals. U.S. approval in 2017; launch in 2018.
- **Suboxone Film** — Buprenorphine and naloxone sublingual film for opioid dependence; faces generic competition. U.S. launch in 2010.
- **Subutex** — Buprenorphine sublingual tablets sold in selected international markets; availability depends on country.
- **OPVEE** — Nalmefene nasal spray for emergency opioid-overdose reversal, approved in 2023. Sales and marketing support discontinued in Q3 2025.
- **Perseris** — Extended-release risperidone injection for adult schizophrenia, approved in 2018. Promotion ended July 2024; the company subsequently ceased manufacturing.

## Achievements

- Sublocade received FDA approval in 2017.
- FDA approved a rapid-initiation protocol and additional Sublocade injection sites in February 2025.
- Sublocade generated $856 million in 2025 net revenue.
- Completed U.S. redomiciliation in January 2026.

## Latest updates

- **2026-10** — On October 15, 94% of votes cast supported the proposed Supernus merger; closing expected November 2, 2026, with the combined company to be named Supernus, Inc.
- **2026-08** — Q2 revenue reached $343 million; Sublocade revenue was $253 million. The companies announced their proposed all-stock merger.
- **2026-02** — Reported 2025 net revenue of $1.239 billion and net income of $210 million.
- **2026-01** — Indivior Pharmaceuticals, Inc. became the U.S. parent on January 23.

## Links

- Website: https://www.indivior.com/
- LinkedIn: https://www.linkedin.com/company/indivior/
- Twitter/X: https://x.com/Indivior
- Instagram: https://www.instagram.com/lifeatindiviorpharma/

---

Profile page: https://yespress.io/indivior
Published by YesPress — https://yespress.io
Last updated: 2026-10-22